Background
==========

Sarcoidosis is a chronic and multisystem granulomatous disease of unknown etiology that can involve almost any organ system \[[@B1]\]. The assessment of overall disease burden is often challenging in sarcoidosis because of the disease\'s various clinical manifestations. Although spirometry and chest radiography are usually used to evaluate disease activity, these measures fail to address extrapulmonary lesions. As in other respiratory diseases, the patient\'s health-related quality of life (HRQOL) may be a useful measure to assess the systemic impact of sarcoidosis \[[@B2]-[@B4]\], and impaired HRQOL has been reported in sarcoidosis \[[@B5]\]. Given that sarcoidosis is a chronic disease for which there is no curative therapy yet \[[@B6]\], HRQOL could be the most important outcome to measure in the management of sarcoidosis. The incidence of sarcoidosis in Japan is 1.01 per 100,000 inhabitants, and 78.7% of patients are symptomatic at diagnosis \[[@B7]\]. Additionally, sarcoidosis has been listed as one of 130 intractable diseases by the Ministry of Health, Labor and Welfare in Japan. Although more than 1,000 patients are newly diagnosed with sarcoidosis and suffer from the disease, to date, no sarcoidosis-specific HRQOL questionnaire has been developed that can be used for the Japanese population.

The Sarcoidosis Health Questionnaire (SHQ), developed by Cox and coworkers in the United States (US), is the only sarcoidosis-specific HRQOL questionnaire \[[@B8]\]. They reported that the SHQ was more sensitive to differences in the number of involved organ systems than both the generic Medical Outcomes Study 36-item short form (SF-36) \[[@B9]\] and the respiratory-specific St. George\'s Respiratory Questionnaire (SGRQ) \[[@B2]\]. We therefore hypothesized that the SHQ would also be a useful measurement of the HRQOL of patients with sarcoidosis in Japan. Hence, we aimed to develop and validate a Japanese version of the SHQ.

Methods
=======

We consecutively enrolled 138 Japanese patients with biopsy-proven sarcoidosis who presented to the Kyoto Central Clinic between June and December 2009. Exclusion criteria included age \<18 years, presence of an active neoplasm, and cognitive and/or reading impairment that prevented completion of the questionnaires.

All patients underwent chest radiography, an electrocardiogram, laboratory blood tests, pulmonary function tests (PFTs), and an echocardiogram. The current extent of organ involvement was assessed by the A Case-Control Epidemiologic Study of Sarcoidosis (ACCESS) Organ Involvement Index \[[@B10]\]. Chest radiographs were classified according to standard radiographic staging: stage 0, normal; stage I, bilateral hilar lymphadenopathy (BHL); stage II, BHL with pulmonary infiltrates; stage III, pulmonary infiltrates without BHL; and stage IV, advanced pulmonary fibrosis \[[@B11]\]. Serum angiotensin converting enzyme (sACE) activity and soluble interleukin-2 receptor were measured as they are known to be serum biomarkers of sarcoidosis \[[@B12],[@B13]\]. PFTs were performed by the standardized method \[[@B14]\]. Left ventricular ejection fraction (LVEF) was calculated and pulmonary arterial systolic pressure (PASP) was estimated as described previously \[[@B15]\]. The Institutional Review Board of the Kyoto Central Clinic approved this cross-sectional study, and all patients provided written informed consent.

HRQOL was assessed by the Japanese versions of the SF-36 \[[@B9],[@B16]\] and the SGRQ \[[@B2],[@B17]\]. The Japanese version of the SHQ was developed following the forward-backward translation procedure with independent translations and counter-translations. The SHQ consists of three domains: Daily Functioning (DF), Physical Functioning (PF), and Emotional Functioning (EF). Each item was scored on a 7-point scale, and each domain and the total score were calculated by dividing the sum of the scores by the number of items. Higher scores indicate better HRQOL on the SHQ and SF-36, but worse HRQOL on the SGRQ. Dyspnea was evaluated using the Japanese version of the Medical Research Council (MRC) dyspnea scale in which a higher score indicates a worse status \[[@B18]\]. Depressive symptoms were evaluated by the Japanese version of the Center for Epidemiologic Study-Depression (CES-D, 20-item version) Scale. In this scale, a higher score indicates more depressed symptoms \[[@B19],[@B20]\].

Data are presented as mean ± standard deviation. Cronbach\'s coefficient α was used to assess the reliability of the questionnaire. Spearman\'s rank correlation test was used to examine the relationships between SHQ scores and the other HRQOL measures (SF-36 and SGRQ scores) and the clinical variables measured. The Mann-Whitney U test was used to compare HRQOL questionnaire scores between patients who differed in the number of sarcoidosis-affected organ systems (organ system involvement). Values of p \< 0.05 were considered statistically significant.

Results
=======

Of the 138 enrolled patients, 16 were excluded because they either did not complete the questionnaires sufficiently for assessment or they had no active organ involvement of sarcoidosis at that time. Table [1](#T1){ref-type="table"} shows the demographics of the remaining 122 patients and their scores on the SHQ, SF-36, SGRQ, MRC, and CES-D.

###### 

Demographics and HRQOL/clinical findings of the study participants (n = 122)

                                           Mean ± SD or n (%)               Range
  ---------------------------------------- -------------------------------- --------------
  Age, years                               56.8 ± 15.5                      24 - 85
  Female                                   74 (60.6%)                       
  Duration of sarcoidosis (months)         108.9 ± 86.2                     2 - 395
  Number of organ systems involved         1.8 ± 0.8                        1 - 5
  Radiographic stage                       37/32/33/15/5                    
  (0/I/II/III/IV)                          (30.3%/26.2%/27.0%/12.3%/4.1%)   
  Blood laboratory tests                                                    
   ACE, IU/L                               17.2 ± 6.5                       3.8 - 41.7
   sIL-2R, IU/mL                           639.9 ± 507.5                    128 - 3772
  Pulmonary function tests                                                  
   FVC, %predicted                         105.8 ± 18.5                     44.3 - 146.4
   FEV~1~, %predicted                      105.8 ± 21.0                     35.0 - 158.7
   DLCO, %predicted                        85.1 ± 17.2                      33.7 - 133.3
  Echocardiogram                                                            
   LVEF, %                                 68.1 ± 11.4                      31.8 - 79.5
   PASP, mmHg                              29.4 ± 5.9                       19.0 - 57.4
  SHQ                                                                       
   Daily Functioning \[[@B1]-[@B7]\]       4.7 ± 1.0                        2.1 - 6.7
   Physical Functioning \[[@B1]-[@B7]\]    5.4 ± 1.0                        2.7 - 6.8
   Emotional Functioning \[[@B1]-[@B7]\]   4.8 ± 1.0                        2.2 - 6.9
   Total \[[@B1]-[@B7]\]                   4.9 ± 0.9                        2.4 - 6.7
  SF-36                                                                     
   Physical functioning \[0-100\]          79.2 ± 20.9                      0 - 100
   Role-physical \[0-100\]                 77.1 ± 27.0                      0 - 100
   Bodily pain \[0-100\]                   71.9 ± 26.7                      0 - 100
   General health perceptions \[0-100\]    50.0 ± 19.7                      0 - 97
   Vitality \[0-100\]                      52.2 ± 23.1                      0 - 100
   Social functioning \[0-100\]            78.6 ± 24.1                      0 - 100
   Role-emotional \[0-100\]                77.7 ± 25.7                      0 - 100
   Mental health \[0-100\]                 66.6 ± 20.5                      5 - 100
  SGRQ                                                                      
   Symptoms \[0-100\]                      39.8 ± 20.6                      0 - 86.5
   Activity \[0-100\]                      29.7 ± 24.9                      0 - 92.5
   Impact \[0-100\]                        14.6 ± 14.6                      0 - 57.3
   Total \[0-100\]                         23.4 ± 16.3                      0 - 71.8
  MRC \[[@B1]-[@B5]\]                      1.8 ± 0.8                        1 - 5
  CES-D \[0-60\]                           12.8 ± 9.3                       0 - 45

The numbers in square brackets represent the theoretical score range.

On the SHQ and SF-36, higher scores indicate better status, while on the SGRQ, MRC, CES-D, lower scores indicate better status.

Abbreviations: HRQOL, health-related quality of life; SD, standard deviation; ACE, angiotensin-converting enzyme; sIL-2R, soluble interleukin-2 receptor; FVC, forced vital capacity; FEV~1~, forced expiratory volume in one second; DLCO, diffusion capacity for carbon monoxide; LVEF, left ventricular ejection fraction; PASP, pulmonary arterial systolic pressure SHQ, Sarcoidosis Health Questionnaire; SF-36, Medical Outcomes Study 36-item short form; SGRQ, St. George\'s Respiratory Questionnaire; MRC, Medical Research Council; CES-D, Center for Epidemiologic Study-Depression Scale

Cronbach\'s coefficient α values of the DF, PF, and EF domains of the SHQ were 0.85, 0.68, and 0.77, respectively, and the α value for the total SHQ score was 0.91. The SHQ total score, as well as the scores for all three domains, were essentially normally distributed (Figure [1](#F1){ref-type="fig"}).

![**Frequency distribution histograms of the total and domain scores on the Sarcoidosis Health Questionnaire**. A higher score indicates better health status. The theoretical score range is from 0 to 7 on the total and all domains. Abbreviations: SHQ, Sarcoidosis Health Questionnaire.](1477-7525-9-34-1){#F1}

The relationships between SHQ scores and the other HRQOL measures and the clinical variables measured are presented in Table [2](#T2){ref-type="table"}. The three SHQ domain scores and the total score all moderately to strongly correlated with the scores on the SF-36 subscales (Spearman\'s correlation coefficient, r~s~= 0.45 to 0.78, all p \< 0.05). They also weakly to strongly correlated with the three component scores and the total score of the SGRQ (r~s~= -0.74 to -0.27, all p \< 0.05). The DF, EF, and total SHQ scores weakly correlated with sIL2-R levels (r~s~= -0.24 to -0.20, all p \< 0.05), while the DF, PF, and total SHQ scores correlated with the percentage of the predicted forced vital capacity (%FVC, one of the PFT measurements) (r~s~= 0.18 to 0.27, all p \< 0.05), but only the PF score correlated with the PASP (r~s~= -0.38, p \< 0.05). All three domain scores and the total SHQ score moderately correlated with scores on the MRC dyspnea scale (r~s~= -0.56 to -0.44, all p \< 0.05) and the CES-D scale (r~s~= -0.70 to -0.39, p \< 0.05).

###### 

Spearman\'s rank correlation coefficients between SHQ scores and other HRQOL measures and clinical variables

                                SHQ-DF   SHQ-PF   SHQ-EF   SHQ-Total
  ----------------------------- -------- -------- -------- -----------
  SF-36                                                    
   Physical functioning         0.54     0.66     0.49     0.60
   Role-physical                0.70     0.60     0.66     0.74
   Bodily pain                  0.68     0.68     0.53     0.68
   General health perceptions   0.78     0.52     0.66     0.74
   Vitality                     0.77     0.54     0.70     0.77
   Social functioning           0.75     0.49     0.74     0.77
   Role-emotional               0.69     0.51     0.69     0.71
   Mental health                0.69     0.45     0.71     0.71
  SGRQ                                                     
   Symptoms                     -0.30    -0.48    -0.27    -0.35
   Activity                     -0.53    -0.71    -0.49    -0.59
   Impact                       -0.49    -0.60    -0.45    -0.53
   Total                        -0.55    -0.74    -0.51    -0.61
  Radiographic stage            \-       \-       \-       \-
  ACE                           \-       \-       \-       \-
  sIL2-R                        -0.24    \-       -0.20    -0.22
  %FVC                          0.18     0.27     \-       0.18
  %FEV~1~                       \-       \-       \-       \-
  %DLCO                         \-       \-       \-       \-
  LVEF                          \-       \-       \-       \-
  PASP                          \-       -0.38    \-       \-
  MRC                           -0.44    -0.56    -0.46    -0.50
  CES-D                         -0.65    -0.39    -0.70    -0.68

Missing data (-) indicate that the relationships were not statistically significant.

Abbreviations: HRQOL, health-related quality of life; DF, Daily Functioning; PF, Physical Functioning; EF, Emotional Functioning; SHQ, Sarcoidosis Health Questionnaire; SF-36, Medical Outcomes Study 36-item short form; SGRQ, St. George\'s Respiratory Questionnaire; ACE, angiotensin-converting enzyme; sIL-2R, soluble interleukin-2 receptor; FVC, forced vital capacity; FEV~1~, forced expiratory volume in one second; DLCO, diffusion capacity for carbon monoxide; LVEF, left ventricular ejection fraction; PASP, pulmonary arterial systolic pressure; MRC, Medical Research Council; CES-D, Center for Epidemiologic Study-Depression Scale

Patients who had involvement of one or two organ system(s) had significantly lower scores than patients who had three or more organ systems involved in the DF domain (p = 0.01), the EF domain (p = 0.03), the total SHQ score (p = 0.04), and in three of the eight subscales of the SF-36 (p \< 0.01 to p = 0.04) (Table [3](#T3){ref-type="table"}). The SGRQ scores were not significantly different between the two groups.

###### 

Relationships between different HRQOL measures and the organ system involvement of sarcoidosis

                                One or two organs   Three or more organs   p
  ----------------------------- ------------------- ---------------------- --------
  SHQ                                                                      
   Daily Functioning            4.8 ± 1.0           4.2 ± 0.9              0.01
   Physical Functioning         5.3 ± 0.9           5.3 ± 1.1              0.94
   Emotional Functioning        4.9 ± 1.0           4.4 ± 0.7              0.03
   Total                        4.9 ± 0.9           4.5 ± 0.8              0.04
  SF-36                                                                    
   Physical functioning         81.0 ± 18.5         69.8 ± 29.4            0.08
   Role-physical                79.8 ± 25.5         63.4 ± 30.7            0.02
   Bodily pain                  73.8 ± 25.3         62.0 ± 31.9            0.11
   General health perceptions   51.5 ± 20.2         42.3 ± 15.5            0.04
   Vitality                     53.4 ± 23.1         45.6 ± 22.3            0.18
   Social functioning           81.0 ± 21.2         61.9 ± 31.0            \<0.01
   Role-emotional               79.8 ± 23.3         67.1 ± 34.1            0.17
   Mental health                67.9 ± 20.4         59.5 ± 20.2            0.10
  SGRQ                                                                     
   Symptoms                     39.6 ± 21.1         41.2 ± 18.7            0.79
   Activity                     29.1 ± 24.9         32.6 ± 25.1            0.53
   Impact                       14.2 ± 14.3         17.0 ± 16.3            0.45
   Total                        22.9 ± 16.3         25.8 ± 16.6            0.44

All data represent mean ± SD.

Abbreviations: HRQOL, health-related quality of life; SHQ, Sarcoidosis Health Questionnaire; SF-36, Medical Outcomes Study 36-item short form; SGRQ, St. George\'s Respiratory Questionnaire

Discussion
==========

In this report, we have demonstrated the reliability of a Japanese version of the SHQ and validated it by examining the correlations between SHQ scores and 1) scores on other HRQOL questionnaires and 2) clinical variables in Japanese patients with sarcoidosis.

The reliability of the translated SHQ was assessed for internal consistency. The Cronbach\'s α values for all three domains and the total SHQ were above the 0.60 required to support construct validity \[[@B21]\], indicating an acceptable level of internal consistency.

The correlations between SHQ scores and SF-36 and SGRQ scores were weakly to strongly significant (\|r~s~\| = 0.27 to 0.75). These findings indicate that while the translated SHQ evaluated the HRQOL of Japanese patients with sarcoidosis, it did not necessarily measure the same aspects as the other HRQOL questionnaires. The SHQ scores were weakly but significantly associated with a serum biomarker (sIL-2R), pulmonary function, and the echocardiographic index. These correlations indicate that the SHQ can evaluate the effects of multiple pathophysiological processes in sarcoidosis that involve several organ systems. Furthermore, the SHQ scores more highly correlated with patient-reported outcomes such as dyspnea (MRC) and depressive symptoms (CES-D) than with physiological measurements. These findings are consistent with our previous findings in other diseases \[[@B17],[@B22],[@B23]\]. In all, these findings indicate that the SHQ could be an effective assessment for a wide range of the manifestations of the disease, including both functional and psychological.

The validity of the SHQ was also shown by comparing the scores between patients who differed in the extent of organ system involvement. The SHQ scores were significantly different between patients with one or two organ system involvement and those with three or more. Furthermore, compared with the SF-36 and the SGRQ, the SHQ was better able to distinguish the HRQOL between these two groups.

The clinical manifestations of sarcoidosis may differ between different ethnic groups. Compared to Western countries, sarcoidosis in Japan is less severe, but has a higher likelihood of ocular and cardiac involvement \[[@B7],[@B24],[@B25]\]. Thus, HRQOL and its relationship with various clinical features may be different in the different populations. This topic should be explored in the future. Furthermore, one limitation of the study was that the responsiveness of the SHQ over time was not examined, because we did not target those who were newly diagnosed or needed to start treatment as subjects for this study.

Conclusions
===========

We have demonstrated the reliability and validity of a Japanese version of the SHQ. The SHQ can evaluate the HRQOL of Japanese patients with sarcoidosis, and when added to routine radiological, serological and physiological evaluations of the disease, can provide valuable additional information. As the SHQ is a disease-specific questionnaire, it can evaluate what the generic SF-36 and respiratory-specific SGRQ do not evaluate.
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